{"filings":[{"id":507924,"accession_number":"0001104659-26-063325","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2026-05-18T22:32:23+00:00","items":["7.01","9.01"],"status":"ready","headline":"Entrada updates corporate presentation; no specific financial or pipeline details disclosed","event_type":"other_material","confidence":"low","bullets":["Filing includes updated corporate presentation (Exhibit 99.1) for use in investor meetings.","Presentation dated May 2026 was furnished under Regulation FD.","No specific changes in financial guidance, pipeline milestones, or leadership disclosed in the filing excerpt.","The full presentation content was not provided in the filing text available for analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94696,"accession_number":"0001689375-26-000027","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entrada reports positive Phase 1/2 data for ENTR-601-44 in DMD; Q1 net loss $39.7M","event_type":"other_material","confidence":"high","bullets":["Cohort 1 of ELEVATE-44-201 met primary safety endpoint: no SAEs, no discontinuations, kidney markers normal.","Statistically significant improvement in Time to Rise velocity versus placebo (p<.05), 3.5x MCID threshold.","Dystrophin increased 2.36% over 4.00% baseline; exon skipping increased 2.31% over 2.66% baseline.","Cash, cash equivalents and marketable securities $254.9M as of March 31, 2026; runway into Q3 2027.","Q1 net loss $39.7M vs $17.3M in Q1 2025; collaboration revenue dropped to $0.9M from $20.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107273,"accession_number":"0001689375-26-000009","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada posts Q4 net loss of $39.2M; cash at $295.7M; DMD program advances","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.2M in Q4 2025 vs net income of $1.1M in Q4 2024; full-year net loss of $143.8M.","Cash, cash equivalents and marketable securities of $295.7M as of Dec 31, 2025; runway into Q3 2027.","DMC recommended initiating Cohort 2 of ELEVATE-44-201 at 12 mg/kg; Cohort 1 data expected Q2 2026.","ELEVATE-45-201 Cohort 1 data on track for mid-2026; ENTR-601-50 regulatory authorization in UK obtained.","Nomination of ENTR-801 for Usher syndrome type 2A; second ocular candidate expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":25421000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107272,"accession_number":"0001689375-26-000003","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Entrada reports ~$296M cash, completes DMD cohort 1, expands pipeline into ocular disease with ENTR-801","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities of ~$296M as of Dec 31, 2025; cash runway into Q3 2027.","Completed dosing of Cohort 1 in global Phase 1/2 MAD study of ENTR-601-44 (exon 44 skipping) for DMD.","On track to report ELEVATE-44-201 data from first cohort in Q2 2026; ELEVATE-45-201 data in mid-2026.","Received UK MHRA authorization for Phase 1/2 ENTR-601-50; expect global initiation by end 2026 and regulatory apps for ENTR-601-51 in 2026.","Expanded into ocular diseases: selected ENTR-801 (Usher syndrome type 2A) as first candidate; expects second candidate in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123619,"accession_number":"0001689375-25-000049","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Q3 net loss widens to $44.1M; DMD pipeline on track for data in 2026","event_type":"earnings","confidence":"high","bullets":["Net loss of $44.1M for Q3 2025, compared to $14.0M net loss in Q3 2024; collaboration revenue fell to $1.6M from $19.6M.","Cash, cash equivalents & marketable securities of $326.8M extended runway into Q3 2027.","ELEVATE-44-201 cohort 1 data on track for Q2 2026; first patient dosed in ELEVATE-45-201 with cohort 1 data expected mid-2026.","Filed UK regulatory authorization for ENTR-601-50; plans to submit EU applications in H2 2026.","Vertex VX-670 (DM1) trial enrollment and dosing on track for completion in H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":24122000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140301,"accession_number":"0001689375-25-000041","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Therapeutics reports Q2 net loss of $43.1M; cash runway into Q2 2027; advances DMD trials","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.1M in Q2 2025 vs net income of $55.0M in Q2 2024; collaboration revenue fell from $94.7M to $2.0M.","Cash, cash equivalents and marketable securities $354M as of June 30, 2025; expected runway into Q2 2027.","First patient dosed in ELEVATE-44-201 for DMD exon 44; data from first cohort expected H1 2026.","Initiated ELEVATE-45-201 for exon 45; first patient dosing on track Q3 2025; cohort 1 data mid-2026.","Expanded leadership: Navid Khan as SVP Medical Affairs, Kiran Patki as SVP Clinical Development; Maha Radhakrishnan joined Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":22508000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157956,"accession_number":"0001104659-25-058536","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entrada Therapeutics stockholders elect three Class I directors, ratify auditor","event_type":"other","confidence":"high","bullets":["Elected Dipal Doshi (27,809,399 for, 429,248 withheld), Kush M. Parmar (24,883,797 for, 3,354,850 withheld), Mary Thistle (27,768,093 for, 470,554 withheld).","Ratified Ernst & Young LLP as independent auditor for FY2025: 30,176,125 for, 74,925 against, 8,476 abstain.","Broker non-votes on director election totaled 2,020,879 shares.","Annual meeting held virtually on June 11, 2025; 30,259,526 shares represented (quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157955,"accession_number":"0001689375-25-000027","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Entrada Therapeutics appoints Maha Radhakrishnan, M.D. to board effective June 1, 2025","event_type":"leadership","confidence":"high","bullets":["Maha Radhakrishnan, M.D. appointed as Class III director; board expanded from 6 to 7 members.","Also appointed to Audit Committee, replacing Kush Parmar, M.D., Ph.D.; Parmar remains chairman.","Current Executive Partner at Sofinnova Investments; former CMO of Biogen (2019-2024).","Initial equity award: option to purchase 38,000 shares vesting over 3 years; annual cash fees of $40,000 + $9,000 Audit Committee retainer.","Appointment takes effect June 1, 2025; serves until 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}